New targets and targeted drugs for the treatment of cancer: An outlook to pediatric oncology

Pediatric Hematology and Oncology

Volumn 28, Issue 7, 2011, Pages 539-555

  Rossig, Claudia ^a   Juergens, Heribert ^a   Berdel, Wolfgang E ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Drug targets; Molecularly targeted therapy; Tumor stroma interactions

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; AZACITIDINE; BEVACIZUMAB; CETUXIMAB; CRIZOTINIB; DASATINIB; DENILEUKIN DIFTITOX; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; LAPATINIB; NILOTINIB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PAZOPANIB; RETINOIC ACID; RETINOID; RITUXIMAB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ASTROCYTOMA; BRAIN TUMOR; BREAST CANCER; CANCER CELL; CANCER THERAPY; CHILDHOOD CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG PENETRATION; DRUG TARGETING; EXPERIENCE; GASTROINTESTINAL TUMOR; GLIOMA; HUMAN; KIDNEY CARCINOMA; LIVER CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MEDULLOBLASTOMA; MICROENVIRONMENT; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; ONCOLOGY; OSTEOSARCOMA; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; T CELL LYMPHOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; HUMANS; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PEDIATRICS; SIGNAL TRANSDUCTION;

EID: 80053067837     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2011.613094     Document Type: Review

References (89)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efcacy and safety of a specifc inhibitorof the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037. (Pubitemid 32267972)
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
3. Houghton PJ, Arceci RJ, eds. Molecularly Targeted Therapy for Childhood Cancer. New York: Springer; 2010.
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N Engl J Med. 2004;350: 2129-2139. (Pubitemid 38637993)
5. Massimino M, Bode U, Biassoni V, Fleischhack G. Nimotuzumab for pediatric difuse intrinsic pon-tine gliomas. Expert Opin Biol Ther. 2011;11:247-256.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
7. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractoryto chemotherapy treatment. JClin Oncol. 1998;16:2659-2671. (Pubitemid 28363029)
8. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
9. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. 2005;41:1349-1361. (Pubitemid 40813013)
10. Pollack IF, Stewart CF, Kocak M, et al. A phase II study of geftinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2011;13:290-297.
11. Jakacki RI, Hamilton M, Gilbertson RJ, et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol. 2008;26:4921-4927.
12. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efcacy and biomarker analyses. Breast Cancer Res Treat. 2008;112:533-543.
13. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26:1993-1999.
14. Dahabreh IJ, Linardou H, Kosmidis P, et al. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: asystematic review and meta-analysis in non-small-cell lung cancer. Ann Oncol. 2011;22:545-552.
15. Mok TS, Wu YL, Tongprasert SY, et al. Geftinib or carboplatin-paclitaxel in pulmonary adenocar-cinoma. N Engl J Med. 2009;361:947-957.
16. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required forpanitumumab efcacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
17. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-1134. (Pubitemid 39296599)
18. Demetri GD, van Oosterom AT, Garrett CR, et al. Efcacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-1338. (Pubitemid 44528723)
19. Janeway KA, Albritton KH, Van Den Abbeele AD, et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009;52:767-771.
20. Lokker NA, Sullivan CM, Hollenbach SJ, et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 2002;62:3729-3735. (Pubitemid 34728854)
21. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12: 4899-4907. (Pubitemid 44338577)
22. Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9:145-160. (Pubitemid 46580316)
23. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic signifcance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89-94. (Pubitemid 32061246)
24. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic signifcance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372-4380. (Pubitemid 35434129)
25. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in frst relapse. Blood. 2011;117:3294-3301.
26. Toretsky JA, Kalebic T, Blakesley V, et al. Te insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fbroblasts. J Biol Chem. 1997;272:30822-30827. (Pubitemid 27527522)
27. Juergens H, Daw NC, Geoerger B, et al. Preliminary efcacy of the anti-insulin like growth factor type 1 receptor antibody fgitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011; in press.
28. Passoni L, Longo L, Collini P, et al. Mutation-independent anaplastic lymphoma kinase overexpres-sion in poor prognosis neuroblastoma patients. Cancer Res. 2009;69:7338-7346.
29. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-2270.
30. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-2259.
31. Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is efective in children with chronic myeloge-nous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006;20:187-192. (Pubitemid 43148651)
32. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27:5175-5181.
33. Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol. 2011;29:839-844.
34. Vitali R, Mancini C, Cesi V, et al. Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model. Int J Cancer. 2009;125:2547-2555.
35. Shor AC, Keschman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and inducesapoptosis in bone sarcoma cellsdependent on SRC kinase for survival. Cancer Res. 2007;67:2800-2808. (Pubitemid 46548969)
36. Creutzig U, Zimmermann M, Dworzak M, et al. Favourableoutcome of patientswithchildhoodacute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haema-tol. 2010;149:399-409.
37. Tiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological diferentiation of human neuroblastoma. Nature. 1985;313:404-406. (Pubitemid 15198727)
38. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neurob-lastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27:1007-1013.
39. Garaventa A, Luksch R, Lo Piccolo MS, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res. 2003;9:2032-2039. (Pubitemid 36687622)
40. Castleberry RP, Loh ML, Jayaprakash N, et al. Phase II window study of R115777 (Zarnesta) in untreated juvenile myelomonocytic leukemia (JMML): a Children's Oncology Group study. Blood. 2005;106:727a.
41. Guha A, Feldkamp MM, Lau N, et al. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 1997;15:2755-2765. (Pubitemid 28004565)
42. Haas-Kogan DA, Banerjee A, Poussaint TY, et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed difuse intrinsic pontine gliomas. Neuro Oncol. 2011;13:298-306.
43. Garber K. Rapamycin may prevent post-transplant lymphoma. J Natl Cancer Inst. 2001;93:1519. (Pubitemid 32998478)
44. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281. (Pubitemid 46849157)
45. Motzer RJ, Escudier B, Oudard S, et al. Efcacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
46. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822-3829.
47. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblas-toma multiforme. Invest New Drugs. 2005;23:357-361. (Pubitemid 40980358)
48. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and fgitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17:871-879.
49. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lym-phoblastic leukemia. Science. 2004;306:269-271. (Pubitemid 39336870)
50. Real PJ, Tosello V, Palomero T, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15:50-58.
51. Deangelo DJ, Stone RM, Silverman LB, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol. 2006;ASCO Annual Meeting Proceedings 24(18S).
52. Bonapace L, Bornhauser BC, Schmitz M, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest. 2010;120:1310-1323.
53. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell. 2004;6:229-240. (Pubitemid 39222036)
54. Major MB, Camp ND, Berndt JD, et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science. 2007;316:1043-1046. (Pubitemid 46799493)
55. Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med. 2009;15:750-756.
56. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562-569.
57. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440. (Pubitemid 34525728)
58. Duvic M, Talpur R, Ni X, et al. Phase2trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31-39. (Pubitemid 46053039)
59. Furlan I, Batz C, Flotho C, et al. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009;113:2867-2868.
60. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498. (Pubitemid 41007864)
61. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-917.
62. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67:1783-1792. (Pubitemid 46383406)
63. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): areport from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55:254-259.
64. Coifer B, Tieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the frst randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040-2045.
65. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis difuse large-B-cell lym-phoma: a randomised controlled trial by the MabTera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-391.
66. Herold M, Haas A, Srock S, et al. Rituximab added to frst-line mitoxantrone, chlorambucil, and pred-nisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986-1992. (Pubitemid 46972781)
67. Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol. 2010;28:3115-3121.
68. Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171-179.
69. Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009;15:6217-6224.
70. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324-1334.
71. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after frst remission in advanced fol-licular lymphoma. J Clin Oncol. 2008;26:5156-5164.
72. Zwaan CM, Reinhardt D, Zimmerman M, et al. Salvage treatment for children with refractory frst or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 2010;148:768-776.
73. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974-977.
74. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blina-tumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493-2498.
75. Handgretinger R, Zugmaier G, Henze G, et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia. 2011;25:181-184.
76. Liersch R, Berdel WE, Kessler T. Angiogenesis Inhibiton. Berlin: Springer; 2010.
77. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fuorouracil, and leu-covorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
78. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142-148.
79. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of beva-cizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008;26:399-405. (Pubitemid 351171691)
80. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
81. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
82. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2011 [Epub ahead of print].
83. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
84. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068.
85. Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2011 [Epub ahead of print].
86. MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol. 2008;26:919-924. (Pubitemid 351398085)
87. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351-1357.
88. Gatzemeier U, von Pawel J, Vynnychenko I, et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with frst-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol. 2011;12:30-37.
89. Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carbo-platin and paclitaxel on ECOG 4599. J Clin Oncol. 2010;28:949-954.